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Abstract
Most patients with brain metastases from malignant melanoma are diagnosed after treatment for
known extracranial metastases and have a poor outcome despite various local and systemic
therapeutic approaches. Here we discuss an unusual case where a 45-year old patient presented
with a brain metastasis as the first symptom of disease and where the presumed primary lesion later
was found in the gastro-intestinal tract. Treatment consisted of sequential surgical removal of a
total of 4 tumor sites (2 extracranially), whole-brain radiotherapy and two radiosurgery
procedures within 13 months. Following her last treatment, the patient has now been in remission
for 20 months. This case illustrates that some patients with multi-organ melanoma manifestations
may benefit from the repeated use of effective local therapeutic approaches and may experience a
quite favourable prognosis.
Introduction
Malignant melanoma is next to lung cancer, the most fre-
quent cause of brain metastasis [1]. These metastases usu-
ally develop late in the course of the disease. Only 7% of
patients had brain metastases disclosed at the time of ini-
tial diagnosis [2]. It is uncommon that melanoma
patients with brain metastases continue to have an occult
primary tumor after initial thorough work-up and staging.
In the study by Fife and coworkers, the figure was 14% [2].
The course of disease is typically characterised by rapid
extracranial progression and short overall survival time
despite various local and systemic treatment approaches.
Here the authors discuss an unusual case where a patient
presented with a brain metastasis as the first symptom of
disease, a presumed primary in the gastro-intestinal tract
and favourable survival and disease-control in the absence
of any systemic therapy.
Case presentation
The patient is a 45-year old caucasian female without seri-
ous previous disease or family history of cancer. In Octo-
ber 2004, she had noted a few days of hypesthesia in her
left leg, followed by slight hemiparesis and a seizure
resulting in hospitalisation. A magnetic resonance imag-
ing (MRI) scan of the brain revealed a tumor in the right
parietal lobe, presumably representing a glioma (Figure
1). In November 2004, a partial resection (because of the
proximity to the motor cortex) was performed. The symp-
toms improved completely and the patient continued on
anticonvulsant therapy. Histology demonstrated a meta-
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static tumor with pigmented cells and positive immuno-
histochemistry for S100, HMB45 and Vimentin.
Staging including examinations of the eyes, head and neck
mucosa and total skin, gynecological evaluation, bone
scintigraphy and computed tomography (CT) scans
showed an enlarged left adrenal gland as the only patho-
logical finding (Figure 2). All routine blood tests and hor-
monal levels were within normal limits. The adrenal mass
was removed completely by laparoscopic surgery and his-
tology corresponded to that of the brain metastasis. Treat-
ment proceeded with whole-brain radiotherapy (WBRT),
10 fractions of 3 Gy. In February 2005, the patient noted
headaches and a decreasing general condition. A MRI scan
disclosed two new brain metastases in the left parietal and
temporal lobe, respectively (Figure 1). While the parietal
tumor could be resected completely, the temporal lesion
was treated with gamma-knife radiosurgery (RS). The
peripheral minimum dose was 15 Gy. In March 2005, the
patient developed abdominal symptoms and a CT scan
showed a right abdominal mass presumably representing
inflammation in and around the vermiform appendix and
ovary (Figure 2). Surgery including ovarectomy and
appendectomy was performed and the histology demon-
strated again the same type of melanoma with all 3 posi-
tive markers as mentioned. The tumor was limited to the
vermiform appendix without spread to peritoneum or
lymph nodes and was judged to be removed completely.
After a symptom-free interval, routine MR evaluation in
November 2005 disclosed tumor progression of the tem-
poral lesion and a second gamma-knife procedure was
performed. Since then, the patient returned to repeated
follow-up examinations including MR and CT scans. The
last one was performed in July 2007. As shown in Figure
1, there is a stable residual abnormality with contrast-
enhancement in the temporal lobe after repeated gamma-
knife treatments, possibly representing treatment effects
rather than active tumor. No other potential signs of dis-
ease were detectable. The patient has a Karnofsky perform-
ance status (KPS) of 80% resulting from slight
concentration and endurance problems. She has never
received systemic treatment during the whole course of
disease, although she initially was interested in participa-
tion in a clinical trial. However, all trials that were open in
Norway at that time did explicitly exclude patients with
brain metastases.
Magnetic resonance imaging scans of the brain Figure 1
Magnetic resonance imaging scans of the brain. Upper left: the first lesion that led to diagnosis of metastatic melanoma. Lower 
left and upper right: 3 months after resection of the first lesion, 2 new metastases were diagnosed. Lower right: status 27 
months after first diagnosis with residual changes after 2 radiosurgery treatments in the temporal lobe and a resection cavity in 
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Discussion
Neurological symptoms as the first sign of malignant
melanoma are relatively uncommon, as is the inability to
identify the primary tumor in patients with brain metas-
tases from this disease [2]. The patient described here, had
an adrenal mass that was detected shortly after diagnosis
of the first brain lesion. Although primary adrenal
melanoma has occasionally been described, the vast
majority of adrenal lesions represent distant metastases
[3]. It appears more likely that the primary tumor was
located in the vermiform appendix, where it became
symptomatic approximately five months after diagnosis
of the disease. Primary melanoma arising from the
mucosal epithelium of the gastrointestinal tract is also a
rare entity and the differentiation between metastatic and
primary tumors is very difficult [4]. However, no other
lesion that might represent the primary was detectable in
this patient.
Radiotherapy plays an important role in palliative treat-
ment in this setting. Patients with a single brain metastasis
managed with surgical resection plus WBRT have a 2-year
survival rate of 20–25% [2]. Besides resection, prognostic
factors included younger age, long disease-free interval
and no concurrent extracranial metastases. In our patient,
both salvage surgery and RS had to be performed rela-
tively soon after WBRT. RS-reirradiation for local progres-
sion finally resulted in long-term control. It has recently
been increasingly adopted that re-irradiation in primary
and metastatic brain tumors might represent a valuable
therapeutic option without unacceptable toxicity risk [5].
RS for melanoma brain metastases was reported to result
in 1-year local control in 49% and overall survival in 25%
of the patients, with survival being dependent on the score
index for radiosurgery (SIR) [6]. The present patient
belonged to the favourable SIR group (age ≤50 years, KPS
>70%, no evidence of systemic disease at the time of RS,
limited number of brain lesions and largest RS-treated
lesion <13 ccm). The gamma-knife group from Pittsburgh
described their results in 244 patients with melanoma
brain metastases [7]. Median survival was 8 months and
brain disease the cause of death in 40.5% of the patients.
Those with controlled systemic disease, single brain
metastasis and KPS 90–100% had better survival. A
smaller recent series reported a median survival of 11
months and 2-year survival rate of 18% [8]. These authors
emphasize that surgery or multiple RS procedures were
associated with prolonged survival.
Computed tomography scans of the abdomen Figure 2
Computed tomography scans of the abdomen. Adrenal gland metastasis (upper scan) and lower abdominal mass resulting from 
inflammation around the melanoma in the vermiform appendix 4 months later (lower scan).Publish with BioMed Central    and   every 
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Throughout the melanoma literature, long-term survival
after complete resection of metastatic disease has been
reported repeatedly [9,10]. Despite new drugs, local
responses after systemic treatment are infrequent, e.g.,
10% in a recent report [11]. However, local response is
significantly associated with longer survival [11]. Based
on these facts and illustrated through the case discussed
here, effective local therapeutic measures including, e.g.,
surgical resection and high-dose stereotactic radiotherapy,
should be considered in patients with favourable prog-
nostic factors and absence of rapid and synchronous
multi-organ spread.
Conclusion
This case illustrates that patients with multi-organ
melanoma manifestations may benefit from the repeated
use of effective local therapeutic approaches and may
experience a quite favourable prognosis.
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